BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock
NASDAQ · BBOT
4.66
Fundamentals
Market cap
$382.43M
Price / Earnings ratio
-2.1x
Price / Sales ratio
N/A
Price / Book ratio
1.2x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About BridgeBio Oncology Therapeutics, Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
SectorHealthcare
IndustryBiotechnology
Employees88
CEODr. Pedro J. Beltran M.D., Ph.D.
IPO DateAug 12, 2025
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Neil Kumar Ph.D. | Executive Chairman | 1979 |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director & Chair of the Advisory Board | 1950 |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical & Development Officer | 1974 |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director | 1971 |
| Mr. Marc Cobo | VP of Finance & Controller | 1981 |
| Mr. Idan Elmelech M.A., M.B.A. | Chief Operating Officer | 1993 |
| Mr. Aaron Chan J.D. | Vice President of Legal | — |
| Mr. Bin Wang Ph.D. | Senior Vice President of Drug Discovery | — |
| Mr. Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls | — |
| Mr. Rui Xu Ph.D. | Senior Vice President of Drug Discovery | — |
Fundamentals
Valuation
Market cap$382.43M
Price-to-sales ratioN/A
Price-to-book value1.18
Price-earnings ratio-2.10
Return on Equity-62.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1,230.15
Income Statement
Average volume640,836
EBITDA$-153.35M
1 year high (52w)$14.87
1 year low (52w)$4.69
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



